Visby Medical Secures $65 Million to Transform At-Home STI Testing with New Technology

Visby Medical™, renowned for its innovations in rapid, at-home diagnostics, has recently announced a significant funding achievement. The company has completed a financing round that raised approximately $55 million, with a potential increase to $65 million. This latest round was spearheaded by Catalio Capital Management, an investment firm known for its commitment to innovative healthcare solutions.

The funding round has attracted the attention of prominent investors, including ND Capital, Cedars Sinai Medical Center, and Pitango Ventures, underscoring the confidence in Visby Medical's vision. This capital infusion aims to accelerate the launch of the company’s groundbreaking FDA-authorized at-home Women's Sexual Health Test. This move positions Visby as a leader in the at-home testing market, which is rapidly evolving to meet consumer demand for privacy and convenience in healthcare.

Strategic Partnerships and Board Expansion

A key player in this funding round, Catalio Capital Management, is expected to enhance Visby Medical’s operational capabilities and market presence. Notably, Isaac Ro, a partner at Catalio, will join the board as an observer, bringing valuable insights from his extensive experience in healthcare investments. Additionally, Chuck Alpuche, COO at Imperative Care and former executive at Insulet Corporation and PepsiCo, will serve as an independent director on the board. His background in operational leadership and cost efficiency will be instrumental in helping Visby streamline its manufacturing processes.

“Partnering with Catalio Capital Management marks a significant milestone for us,” stated Adam de la Zerda, PhD, founder and CEO of Visby Medical. “This funding will empower us to fulfill our mission of providing consumers with reliable, lab-accurate health information from the comfort of their homes.”

Revolutionary Testing Technology

Visby’s Women's Sexual Health Test is novel in that it serves as the first single-use, disposable PCR diagnostic test, delivering results within 30 minutes through a user-friendly smartphone application. Once results are obtained, users are instantly connected to telemedicine providers for professional consultation and treatment options, significantly improving the accessibility and privacy of healthcare services. The test is scheduled for release in July 2025, made available through major direct-to-consumer channels.

Industry Significance

This initiative not only highlights Visby Medical’s innovative approach to diagnostics but also addresses a crucial need for easy access to sexual health testing, particularly for women. The emphasis on at-home testing products reflects a broader trend in the healthcare industry toward personal empowerment and preventative care through technology. The participation of established investors is a nod to the growing confidence in home diagnostics as a legitimate alternative to traditional testing methods.

As Visby Medical prepares for this new chapter fuelled by fresh funding and expert guidance, it aims to redefine the landscape of healthcare accessibility, making essential diagnostic tools safer and more convenient for all.

About Visby Medical

Founded in 2012, Visby Medical is on a mission to revolutionize infectious disease diagnostics, providing both patients and healthcare professionals with the tools to accurately test for infections anytime and anywhere. Their innovative technology platform ensures that PCR tests can be conducted rapidly, with results delivered faster than traditional methods. Visby is committed to expanding its offerings to include a broader range of at-home diagnostics, reflecting the company's dedication to improving public health outcomes.

With Visby Medical's new financial backing and clear growth trajectory, the future of at-home diagnostics looks brighter than ever.